BUZZ-Aeterna Zentaris Inc: Data Safety Monitoring Board recommends continuing late-stage trial
** Drug developer's U.S.-listed shares up 10.3 pct at $0.64 premarket
** Independent Data Safety Monitoring Board recommended Friday late-stage trial of company's experimental drug to treat type of cancer continue as planned
** Recommendation follows interim analysis of drug, zoptarelin doxorubicin, used to treat cancer arising from uterus lining
** Up to Monday's close, stock gained 82.3 pct this year
© Thomson Reuters 2017 All rights reserved.